Mednet Logo

How would you manage a patient with JAK2-positive PV who is not responding to hydroxyurea or IFN-alpha for cytoreduction?

This is in the setting of a patient who is now on ruxolitinib with rising leukocytosis and thrombocytosis, but cannot be on aspirin due to recent bleed.
3 Answers
Mednet Member
Mednet MemberInvited Expert
Hematology · Mayo Clinic Arizona
Answered on · Updated on

I would first evaluate for secondary von Willebrand. Continue ruxolitinib, and try to maximize dose. If HGB well controlled and platelets continue to increase, I would check iron, and replace it gently to see if that would help the platelets. If that isn’t possible, or replacing iron doesn't help pl...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Hematology · Karmanos Cancer Institute, Wayne State University
Answered on

I have had success with anagrelide in uncontrolled thrombocytosis despite first line therapy. Controlling the platelet count may help with the bleeding which could be sec to acquired VWD (recommend testing pt).

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Hematology · Johns Hopkins University
Answered on

Hydroxyurea resistance is well-documented in MPN patients. The real questions are, is the patient asymptomatic or does the patient require a surgical procedure and has a prolonged ristocetin cofactor assay? For the latter, if it is a minor procedure (dental or dermatologic), tranexamic acid should b...

Join for free or sign in to see the full answer